Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Immune-mediated forms of pericarditis are still poorly understood conditions 1-3. One of these is certainly the post-pericardiotomy syndrome (PPS), a common complication of cardiac surgery, which can prolong recovery of the patient and duration of hospitalization, but also be significantly disabling and even life-threatening1. It has been hypothesized that PPS may relate to an non-sustained autoreactive reaction to pericardial autoantigens released after cardiac surgery, as well as a non-specific post-operative inflammatory status1. Thus, it is not surprising that PPS has recently been shown to be effectively prevented by a very old drug, colchicine, in the Colchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS) trial4. Colchicine is an old drug, with anti-inflammatory and immunomodulatory effects. The premise of the COPPS substudy, recently published by Dr Imazio, is that the same inflammatory milieau could contribute to the onset of postoperative atrial fibrillation (POAF), and therefore that colchicine might also be effective in POAF prevention5.
The aim of the Colchicine for the Prevention of the Post-Pericardiotomy Syndrome (COPPS) POAF substudy was to test the efficacy and safety of colchicine for the prevention of POAF after cardiac surgery.
The COPPS POAF substudy included 336 patients (mean age, 65.7±12.3 years; 69% male) of the COPPS trial, a multicenter, double-blind, randomized trial. Substudy patients were in sinus rhythm before starting the intervention (placebo/colchicine 1.0 mg twice daily starting on postoperative day 3 followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, halved doses for patients <70 kg or intolerant to the highest dose). The substudy primary end point was the incidence of POAF on intervention at 1 month. Despite well-balanced baseline characteristics, patients on colchicine had a reduced incidence of POAF (12.0% versus 22.0%, respectively; P=0.021; relative risk reduction, 45%; number needed to treat, 11) with a shorter in-hospital stay (9.4±3.7 versus 10.3±4.3 days; P=0.040) and rehabilitation stay (12.1±6.1 versus 13.9±6.5 days; P=0.009). Side effects were similar in the study groups.
The authors’ conclusion was that colchicine seems safe and efficacious in the reduction of POAF with the potentiality of halving the complication and reducing the hospital stay.
Clinical Trial Registration— Unique identifier: NCT00128427.
The study by Imazio5 is very promising and in keeping with a number of well-conducted studies by the same group of researchers showing that colchicine prevents acute6, recurrent pericarditis7 and PPS4. The present study5 has limitations, in particular it is a post-hoc analysis on a small number of patients and needs confirmation on a larger, multicenter patient population. In addition, 43% of the POAF occurred before the onset of colchicine treatment. Since colchicine was started on postoperative day 3, it is unclear whether the drug would be equally effective in preventing POAF on day 1 or 2. To this end another study (such as starting colchicine before the operation) is needed to confirm efficacy as well as safety.
The only independent predictor of POAF risk was an increased (>45 mm) left atrial anteroposterior diameter by echocardiography. This is an important point. In fact, more data would be needed to clarify who are the surgical patients at risk of POAF development, to target possible preventive strategies to those at high risk. Of note, also perioperative beta-blocker use had a protective effect, and statistically more potent than colchicine5.
More experimental work is needed to understand the pathogenesis of POAF. So far surgery-related pericardial inflammation, autonomic disturbance, changes in plasma volume regulation and ionic disturbance are all plausible causes, as well as atrial trauma and ischemia or even subepicardial atrial myocarditis triggering atrial fibrillation8. The relative importance of these factors or their combination may differ in distinct patient subsets. Similarly, more research should better clarify the mechanisms of action of colchicine in pericardial inflammatory conditions. Colchicine blocks microtubule assembly and can actively disrupt microtubules, in addition it suppresses the release of a c hemotactic factor from neutrophil lysosomes, leading to reduction in neutrophil activation, in endothelial cell adhesion and migration to injured tissues. In addition, colchicine might have an effect on the microtubules of atrial myocytes, which modulate the phosphorylation of calcium channels, possibly affecting the response of atrial myocytes with an anti-sympathetic activity.
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 BIOT
06903Sophia Antipolis, FR
© 2017 European Society of Cardiology. All rights reserved